Table 1 Results of economic (cost) studies
From: Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease
Country | UK [11] | US [12] | US [12] | Canadian [14] | Canadian [13] | French [4] | French [4] |
|---|---|---|---|---|---|---|---|
Cost year | ? (1996–1997) | ? (1994–1996) 1995* | ? (1994–1996) 1995* | 1997 | 1999 | 1996 | 1996 |
Patient group | UK only (n = 191) | US only (n = 936) | All ESSENCE patients | Canadian only | Canadian | French only | All ESSENCE |
(n = 1259) | hypothetical cohort | (n = 133) | patients | ||||
Cost-effectiveness | 30 days | 30 days | 30 days | 1 year | 30 days | 30 days | 30 days |
assessed at | |||||||
Currency | £UK | $US | $US | $CAN | $CAN | FF | FF |
Cost savings | |||||||
Base case 1 | 23.68 | 763 | 661 | 1485 | 44 | 9993 | 1555 |
Base case 2 | na | 1172 | 688 | na | na | 2804 | 1014 |
Sensitivity analysis best case | Not available for cost differences | Net costs in only 14%**and 6%***of 200 | Not available | 3167 | 435 | 12019 | 1876 |
Sensitivity analysis worst | bootstrap samples | -174 | -299 | 1518 | 542 | ||
case | |||||||
In £UK (in cost year as above) | |||||||
Base case 1 | 23.68 | 499 | 432 | 812 | 25 | 980 | 152 |
Base case 2 | na | 766 | 450 | na | na | 275 | 99 |
Sensitivity analysis best case | Not available for cost differences | Net costs in only 14%** and 6%*** of 200 | Not available | 1733 | 247 | 1178 | 184 |
Sensitivity analysis worst | bootstrap samples | -95. Net costs in only | -170 | 149 | 53 | ||
case | 3% of 1000 bootstrap | ||||||
samples |